AU2017216288B2 - Novel combinatorial therapies of neurological disorders - Google Patents

Novel combinatorial therapies of neurological disorders Download PDF

Info

Publication number
AU2017216288B2
AU2017216288B2 AU2017216288A AU2017216288A AU2017216288B2 AU 2017216288 B2 AU2017216288 B2 AU 2017216288B2 AU 2017216288 A AU2017216288 A AU 2017216288A AU 2017216288 A AU2017216288 A AU 2017216288A AU 2017216288 B2 AU2017216288 B2 AU 2017216288B2
Authority
AU
Australia
Prior art keywords
acamprosate
piperazin
phenylsulfonyl
baclofen
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017216288A
Other languages
English (en)
Other versions
AU2017216288A1 (en
Inventor
Daniel Cohen
Rodolphe HAJJ
Serguei Nabirotchkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharnext SA
Original Assignee
Pharnext SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext SA filed Critical Pharnext SA
Publication of AU2017216288A1 publication Critical patent/AU2017216288A1/en
Application granted granted Critical
Publication of AU2017216288B2 publication Critical patent/AU2017216288B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017216288A 2016-02-05 2017-02-03 Novel combinatorial therapies of neurological disorders Ceased AU2017216288B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPEP16305128.7 2016-02-05
EP16305128 2016-02-05
EPEP17152720.3 2017-01-23
EP17152720 2017-01-23
PCT/EP2017/052470 WO2017134280A1 (en) 2016-02-05 2017-02-03 Novel combinatorial therapies of neurological disorders

Publications (2)

Publication Number Publication Date
AU2017216288A1 AU2017216288A1 (en) 2018-08-09
AU2017216288B2 true AU2017216288B2 (en) 2022-06-02

Family

ID=58044028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017216288A Ceased AU2017216288B2 (en) 2016-02-05 2017-02-03 Novel combinatorial therapies of neurological disorders

Country Status (6)

Country Link
US (1) US10799499B2 (https=)
JP (1) JP7027318B2 (https=)
CN (1) CN109069450A (https=)
AU (1) AU2017216288B2 (https=)
CA (1) CA3012900A1 (https=)
WO (1) WO2017134280A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512174A (ja) * 2018-01-29 2021-05-13 ファーネクストＰｈａｒｎｅｘｔ アセチルコリンエステラーゼ阻害剤療法に対する反応性を失った患者におけるアルツハイマー病のバクロフェン及びアカンプロセートを用いた療法
US20220401404A1 (en) * 2019-02-05 2022-12-22 The Regents Of The University Of California Co-Administration Therapy to Prevent Neurodegeneration and Enhance Neuroprotection
CN114181201B (zh) * 2020-09-15 2023-12-01 香港科技大学 作为针对各种神经退行性疾病的潜在治疗剂的新化合物
WO2025151884A1 (en) * 2024-01-12 2025-07-17 Parsons C Lowell Use of glycosaminoglycan sulfated polysaccharides such as sodium pentosan polysulfate in combination with permeation agents to treat alzheimer's disease

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080580A2 (en) * 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
WO2008113818A1 (en) * 2007-03-21 2008-09-25 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
WO2009074607A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
EP2282778A2 (en) * 2008-04-29 2011-02-16 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
WO2014037417A1 (en) * 2012-09-05 2014-03-13 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
EP2796132A1 (en) * 2011-03-01 2014-10-29 Pharnext Baclofen and acamprosate based therapy of neurological disorders
US20140371229A1 (en) * 2011-03-01 2014-12-18 Pharnext New therapeutic approaches for treating parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080580A2 (en) * 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
WO2008113818A1 (en) * 2007-03-21 2008-09-25 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
WO2009074607A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
EP2282778A2 (en) * 2008-04-29 2011-02-16 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
EP2796132A1 (en) * 2011-03-01 2014-10-29 Pharnext Baclofen and acamprosate based therapy of neurological disorders
US20140371229A1 (en) * 2011-03-01 2014-12-18 Pharnext New therapeutic approaches for treating parkinson's disease
WO2014037417A1 (en) * 2012-09-05 2014-03-13 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lanctôt KL, Rajaram RD, Herrmann N. Therapy for Alzheimer's Disease: How Effective are Current Treatments? Ther Adv Neurol Disord. 2009 May;2(3):163-80. doi: 10.1177/1756285609102724. PMID: 21179526; PMCID: PMC3002627. *
XABIER CODONY ET AL, "5-HTreceptor and cognition", CURRENT OPINION IN PHARMACOLOGY, vol. 11, no. 1, doi:10.1016/J.COPH.2011.01.004, ISSN 1471-4892, (2011-01-01), pages 94 - 100, (2011-01-28) *

Also Published As

Publication number Publication date
JP2019504101A (ja) 2019-02-14
AU2017216288A1 (en) 2018-08-09
CA3012900A1 (en) 2017-08-10
US20190111054A1 (en) 2019-04-18
WO2017134280A1 (en) 2017-08-10
US10799499B2 (en) 2020-10-13
CN109069450A (zh) 2018-12-21
JP7027318B2 (ja) 2022-03-01

Similar Documents

Publication Publication Date Title
US10434109B2 (en) Compositions for treating neurological disorders
EP2560631B1 (en) Baclofen and acamprosate based therapy of neurogical disorders
AU2012222348B2 (en) New compositions for treating neurological disorders
AU2015217796B2 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
AU2017216288B2 (en) Novel combinatorial therapies of neurological disorders
US9931326B2 (en) Composition comprising torasemide and baclofen for treating neurological disorders
JP2019504101A5 (https=)
AU2018258970B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
EP3411025A1 (en) Novel combinatorial therapies of neurological disorders
IL256992A (en) Treatment of neurological disorders based on baclofen and acamprosate
HK1197729A (en) Baclofen and acamprosate based therapy of neurological disorders
HK1182615B (en) Baclofen and acamprosate based therapy of neurogical disorders
NZ614267B2 (en) New compositions for treating neurological disorders
NZ614184B2 (en) Baclofen and acamprosate based therapy of neurogical disorders
HK1190607B (en) New compositions for treating neurological disorders
HK1190607A (en) New compositions for treating neurological disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired